MedTrace Logo

Resveratrol's Effects in Diabetic Nephropathy

NCT02704494 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-10-05

No results posted yet for this study

Summary

The aim of this study is to evaluate the safety and effects of resveratrol in treatment of diabetic nephropathy.

Conditions

  • Diabetic Nephropathy

Interventions

DRUG

Resveratrol

Resveratrol 500mg daily

DRUG

Placebo

Placebo 1 capsule daily

DRUG

Losartan

Losartan 12.5mg daily

Sponsors & Collaborators

  • Shiraz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Gholamhossein Ranjbar Omrani, MD · Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences

  • Jamshid Roozbeh, MD · Shiraz Nephrology and Urology Research Center, Shiraz University of Medical Sciences

  • Azar Sattarinejad, MD · Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences

  • Mesbah Shams, MD · Endocrine and Metabolism Research Center, Shiraz University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02704494 on ClinicalTrials.gov